Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Zhongkai Shi"'
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e22605 (2011)
Few other diseases exert such a huge toll of suffering as influenza. We report here that intranasal (i.n.) administration of E1/E3-defective (ΔE1E3) adenovirus serotype 5 (Ad5) particles rapidly induced an anti-influenza state as a means of prophyla
Externí odkaz:
https://doaj.org/article/61fa44e8ef6641c5828f8ef13c25b721
Autor:
Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, Michele Tameris, Soren T. Hoff, Zhongkai Shi, Dereck Tait, Ingrid Kromann, Morten Ruhwald, Kathryn Tucker Rutkowski, Barbara Shepherd, David Hokey, Ann M. Ginsberg, Willem A. Hanekom, Peter Andersen, Thomas J. Scriba, Mark Hatherill, Rachel Elizabeth Oelofse, Lynnett Stone, Anne Marie Swarts, Raida Onrust, Gail Jacobs, Lorraine Coetzee, Gloria Khomba, Bongani Diamond, Alessandro Companie, Ashley Veldsman, Humphrey Mulenga, Yolundi Cloete, Marcia Steyn, Hadn Africa, Lungisa Nkantsu, Erica Smit, Janelle Botes, Nicole Bilek, Simbarashe Mabwe
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 199:220-231
Global tuberculosis (TB) control requires effective vaccines in TB-endemic countries, where most adults are infected with Mycobacterium tuberculosis (M.tb).We sought to define optimal dose and schedule of H56:IC31, an experimental TB vaccine comprisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db667cfaad31d5da81491944c48fd269
https://doi.org/10.1164/rccm.201802-0366oc
https://doi.org/10.1164/rccm.201802-0366oc
Autor:
Danyang Li, Yuxin Pang, Min Zhou, Jiping Qi, He Wu, Ruihua An, Ze Zhang, Zhongkai Shi, Nana Liu
Publikováno v:
Brain research bulletin. 148
Aberrant c-Jun N terminal kinase (JNK) activation is broadly involved in the pathogenesis of several acute and chronic neurological diseases. However, the mechanism of JNK activation leading to aggravation of injury after ICH remains unclear. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba893349b3fe2f60e44dfe4f146d50b2
https://pubmed.ncbi.nlm.nih.gov/30935978
https://pubmed.ncbi.nlm.nih.gov/30935978
Autor:
Colleen Krohn, Zhongkai Shi, Hadn Africa, Gregory D. Hussey, Bruce McClain, Yolande Brown, Hassan Mahomed, Søren T. Hoff, Lebohang Makhethe, Margaret A Snowden, Hennie Geldenhuys, Mark Hatherill, Elisma Schoeman, Angelique Kany Kany Luabeya, Thomas J. Scriba, Sara Suliman, Cheryl L. Day, Ingrid Kromann, Erica Smit, Michele Tameris, E. Jane Hughes, Peter Bang, Benjamin M. Kagina, Peter Andersen, Willem A. Hanekom
Publikováno v:
Vaccine. 33:4130-4140
Background H56:IC31 is a candidate tuberculosis vaccine comprising a fusion protein of Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label phase I trial assessed the safety and immunogenicity of H56:IC31 in healthy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d4d0e6d7b77f74bfee22748910708f9
https://doi.org/10.1016/j.vaccine.2015.06.051
https://doi.org/10.1016/j.vaccine.2015.06.051
Autor:
Hassan Mahomed, J. Bruce McClain, Mark Hatherill, H :Ic Trial Study Groupa, Zhongkai Shi, Hennie Geldenhuys, Thomas J. Scriba, Helen Mearns, Michele Tameris, Sean Bennett, Michele van Rooyen, Guy de Bruyn, Ryall Robert P, David A. Hokey, David Miles, Peter Andersen, Søren T. Hoff, Willem A. Hanekom, Ingrid Kromann
Publikováno v:
Vaccine. 33:3592-3599
Background New, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4:IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B, formulated in IC31 adjuvant. We as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a713c0cd47a6d2c1c82f5aff6a54d8
https://doi.org/10.1016/j.vaccine.2015.05.036
https://doi.org/10.1016/j.vaccine.2015.05.036
Autor:
Limin Wijaya, Zhongkai Shi, Julaihabee A. Kassim, Jenny G. Low, Lin-Fa Wang, Jing Zhao, Yvonne Fu Zi Chan, Shirin Kalimuddin, Helen M. L. Oh, Abigail W.L. Wong
Publikováno v:
Vaccine. 35(51)
Background Human Rabies infection continues to be potentially fatal despite the availability of post-exposure prophylaxis with rabies vaccine. The PIKA Rabies vaccine adjuvant is a TLR3 agonist and has been shown to be safe and immunogenic in clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e1e22cd8da6ce4482dc11affef18127
https://pubmed.ncbi.nlm.nih.gov/29174316
https://pubmed.ncbi.nlm.nih.gov/29174316
Publikováno v:
Cancer Research. 79:4130-4130
Background: YS-ON-001 is a complex containing synthetic double-strand RNA, a toll-like receptor 3 (TLR3) agonist. TLR3 agonist stimulates antigen-presenting cells, increases T, NK, NKT cells and decreases regulatory T cells (Tregs) and myeloid-derive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::942d0f0fa85199b2e4823024471ab607
https://doi.org/10.1158/1538-7445.am2019-4130
https://doi.org/10.1158/1538-7445.am2019-4130
Autor:
Tivanka S. DeSilva, Zhongkai Shi, Craig A. Elmets, Kent R. Van Kampen, Chun Ming Huang, De Chu C. Tang, Masato Yamamoto
Publikováno v:
PROTEOMICS
We created an anti-tumor vaccine by using adenovirus as a vector which contains a cytomegalovirus early promoter-directed human carcinoembryonic antigen gene (AdCMV-hCEA). In an attempt to develop the skin patch vaccine, we epicutaneously vaccinated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de5499b27d2f53498d380a254d722fa3
https://doi.org/10.1002/pmic.200401114
https://doi.org/10.1002/pmic.200401114
Publikováno v:
Chinese medical journal. 127(19)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::42ae876c8f9a71c16f1a54f0c9d99056
https://pubmed.ncbi.nlm.nih.gov/25269923
https://pubmed.ncbi.nlm.nih.gov/25269923
Autor:
Kent R. Van Kampen, De-chu C. Tang, Zhongkai Shi, Guang Yang, Laura J. Cain, Craig A. Elmets, Mingtao Zeng, Felix Siegel
Publikováno v:
Journal of Virology. 75:11474-11482
The effectiveness of vaccination programs would be enhanced greatly through the availability of vaccines that can be administered simply and, preferably, painlessly without the need for timed booster injections. Tetanus is a prime example of a diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf09fba430571acb4c7bef1a2810e95
https://doi.org/10.1128/jvi.75.23.11474-11482.2001
https://doi.org/10.1128/jvi.75.23.11474-11482.2001